RARE
Ultragenyx Pharmaceutical Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 2 to Mar 10 ▼ 4 days of insider sells: $1.9M by 5 insiders, avg $22.69
- May 1 to May 5 ▼ 2 days of insider sells: $125.2K by 2 insiders, avg $24.90
- Aug 3 ▼ 2 insiders sell $164.4K at $24.92
- Sep 3 ▼ 5 downgrades
- Sep 3 ▼ 1 insider sell $2.3K at $13.99
- Sep 15 ▼ 1 insider sell $17.4K at $13.57
- Sep 17 ▲ Ultragenyx announced FDA approval of FAYUVI (UX-101) as the first-ev…
- Sep 17 FDA: Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the…
- Sep 29 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Oct 13
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 15 ▼ 1 insider sell $107.9K at $15.27
- Oct 28 HSR Early Termination: C.H. Boehringer Sohn AG & Co. KG…
Signal stack
Where each data set points today.
- InsidersBEARISH
8 insiders sold $3.0M.
- InstitutionsMIXED
Q3 2026: 38 added (4 new), 32 trimmed or exited. Largest new: Hrt Financial $11.9M, Jane Street Group $10.5M.
- AnalystsBULLISH
16 of 27 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate −$0.929 → $0.655 over 90 days. 2 up, 0 down in 30 days.
- Short sellersBUILDING
Short interest +17.3% to 23.62M shares. 8.3 days to cover, ≈23.2% of shares.
- TrendUPTREND
4% above its 50-day average.
- SocialQUIET
Crowd 58° (warm) this week from 2 mentions: 1 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | ADD | $20.2M |
| Jefferies Financial Group Inc. | ADD | $20.1M |
| HRT FINANCIAL LP | NEW | $11.9M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $11.7M |
| RAYMOND JAMES FINANCIAL INC | DOUBLED | $11.5M |
| CITIGROUP INC | DOUBLED | $11.5M |
| MORGAN STANLEY | TRIM | $11.3M |
| Jump Financial, LLC | DOUBLED | $10.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
27 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Citigroup MAINTAIN | Buy |
| Nov 5, 2026 | Barclays MAINTAIN | Overweight |
| Nov 4, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 4, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 4, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 4, 2026 | Goldman Sachs MAINTAIN | Neutral |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Horn Howard Chief Financial Officer Oct 15, 2026 | SELL | $107.9K |
Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 15, 2026 | SELL | $17.4K |
Huizenga Theodore Alan SVP, Chief Accounting Officer Sep 3, 2026 | SELL | $2.3K |
Parschauer Karah Herdman EVP and Chief Legal Officer Aug 3, 2026 | SELL | $47.3K |
Horn Howard Chief Financial Officer Aug 3, 2026 | SELL | $117.0K |
Horn Howard Chief Financial Officer Jul 1, 2026 | SELL | $155.6K |
Sanders Corazon (Corsee) D. Director Jun 15, 2026 | SELL | $50.1K |
Parschauer Karah Herdman EVP and Chief Legal Officer Jun 15, 2026 | SELL | $46.8K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.66 | -$1.04–$2.46 | +215.1% | $234.1M |
| Next Q | -$0.04 | -$0.45–$0.63 | +90.9% | $198.7M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 2 press releases · 4 bullish · 4 bearish · 1 mixed · 11 neutral- NEUTRAL SC 13G/ANov 13, 2026
AQR Capital Management filed an amended Schedule 13G disclosing a 0.64% passive stake in…
AQR's stake is minimal and passive; no material impact on the stock. Monitor for any future 13D conversion if the position grows, but this filing is routine.
- NEUTRAL SC 13GNov 10, 2026
State Street Corporation filed a Schedule 13G disclosing a 7.6% passive stake in Ultragenyx…
State Street's passive 7.6% stake adds to the existing passive positions from Vanguard (8.6%) and Madison Avenue Partners (6.4%), bringing total disclosed passive ownership to ~22.6%. Monitor for…
- MIXED 8-KNov 3, 2026
Ultragenyx completed the sale of a Rare Pediatric Disease PRV for $210M in gross proceeds (net…
Monitor closing of the second PRV sale ($203M) expected this month and Q4 2025 results for restructuring charge impact and initial GENGLYCOS/FAYUVI launch revenue. The path to 2027 GAAP…
- BEARISH PRESS-RELEASENov 3, 2026
Ultragenyx reported Q3 2026 revenue of $173M (up 8% YoY from $160M) and a net loss of $118M ($1.16…
The EPS and revenue miss, combined with pipeline terminations and a 20% workforce reduction, signal near-term operational stress despite the two FDA approvals. The PRV sales provide a cash buffer…
All RARE filing & press-release reports (22)
- SC 13G/A reportNov 13, 2026
- SC 13G reportNov 10, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- SC 13G/A reportOct 30, 2026
- SC 13G reportOct 20, 2026
- 8-K reportOct 19, 2026
- 8-K reportOct 14, 2026
- 8-K reportOct 7, 2026
- PRESS-RELEASE reportSep 17, 2026
- 8-K reportSep 2, 2026
- PRESS-RELEASE reportSep 1, 2026
- 8-K reportAug 11, 2026
- 8-K reportAug 4, 2026
- CLUSTER reportAug 4, 2026
- CLUSTER reportJun 15, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportMay 1, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportApr 2, 2026
- DEFA14A reportMar 27, 2026
- CLUSTER reportMar 2, 2026